🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📌Our new study from the Turkish Oncology Group Kidney Cancer Consortium just published! 📌Uric acid level is prognostic factor for OS in patients with mRCC treated with Nivolumab Yüksel Ürün Emre Yekedüz Hatice Bölek

Always inspiring for me to see the support of Yüksel Ürün to young oncologists 👏👏 Great to see my dear friend Emre Yekedüz following the steps in supporting the new generation and being a role model for them ⭐️⭐️ Sky is the limit for TKCC 💯💯 Hatice Bölek Serhat Sekmek

23P – #ESMOGI25 GITuD real-world study, 44% of dMMR/MSI-H CRCs (MLH1–/MAPK WT) had actionable alterations (NTRK, RET) vs 0% in non-CRC. NTRK fusions were associated with worse 5-year OS (33% vs 100%, p=0.034), suggesting a role in primary resistance to ICI.

🚨 Breaking the Immunotherapy Plateau Most cancer patients face primary or secondary resistance to treatment. 🔑 New strategies highlight: ✔️ Targeting T cells ✔️ Inhibiting angiogenesis OncoAlert #cancer #Oncology #MedX doi.org/10.1016/j.ejca…

⚠️Publication alert ⚠️ Our new paper from "Turkish Oncology Group Kidney Cancer Consortium" just OUT! Huge congrats to Serhat Sekmek and all the team! Yüksel Ürün OncoAlert #KidneyCancer #MedX #Oncology 👉doi.org/10.1080/175074…

tandfonline.com/eprint/D7EVPHK… 🆕Our latest study is now out in Experts Review of Anti Cancer Therapy. 🧠ICIs appear safe in patients with chronic hepatitis B 📉 Of the 65 patients, 15 (23.0%) experienced irAEs of Grade 1–2. 1 (1.5%) patient had grade 3 pneumonitis

Thanks LARVOL ONCO BRUNO for the list and other informative data analyses in the oncology!

Bu grafik diyor ki: 1800’de ortalama yaşam süresi 32 yıldı! 1950’de 48 yıl… Şimdi? 70’e dayandı! “Eskiden her şey doğaldı, insanlar daha sağlıklıydı” diyenlere selam olsun: Atalarımız daha uzun değil, daha kısa yaşadı. Modern tıp ve aşılar, antibiyotikler, temiz su, hijyen bizi

Science is better when it’s shared. I’d rather have more young researchers each publish something meaningful than 1 person chasing all the spotlight. Let them lead. Let them grow. Because mentorship isn’t about control, it’s about creating space. The future of medicine depends

Happy to share that I’ve been accepted into the Journal of Clinical Oncology Reviewer Trainee Program 🎉 We had our first meeting today. Peer review is the backbone of scientific publishing. I hope to contribute to this essential process.Many thanks to ASCO for this opportunity! #JCO #PeerReview

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow Hatice Bölek from Ankara Üniversitesi ! ⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from

Very important, clinically relevant question! Why does ICI re-challenge show limited benefit in metastatic kidney cancer? Is it the tumor microenvironment? Immune exhaustion? Or our sequencing strategies? OncoAlert KidneyCAN IKCC Kidney Cancer Ankara Üniversitesi Tıp Fakültesi

📢 Our review on sarcopenic obesity and cancer outcomes is out! ⚠️ It’s not just about weight-it’s biology. 🧬 Tumor-promoting environment 💊 Lower treatment efficacy-worse survival 💡Should we dose by lean mass instead of BSA? sciencedirect.com/science/articl… #Oncology #Cancer #obesity

As a leader, your success isn’t measured by being the smartest in the room. Real leadership is when you elevate the room, when you empower, teach, and inspire others to grow smarter, stronger, bolder. Because when the team rises, we all win. #Leadership

📺I briefly summarized the second line treatment of biliary tract cancers 🔵Thanks VuMedi for the kind invitation! 🔵Link for the video recording (25th June) 👇 vumedi.com/video/advancin… VuMedi Oncology OncoAlert #Cancer #Oncology #MedX #biliary #cholangiocarcinoma

🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior

Thanks LARVOL for their kind invitation! We talked about #ESMOGI25 By the way, the modern oncology is about data and how to collect, handle and interpret it. I appreciate and thanks LARVOL on their job 🟣

🥁Join us to discuss novel/promising therapies in muscle-invasive bladder cancer! Yüksel Ürün #TumorBoardTuesday #MedX

🔖 Don't forget to join us this evening! We will discuss how to handle neoadjuvant setting of bladder cancer in the era of novel/promising therapies! All options are on the table even bladder-sparing approaches! Yüksel Ürün #TumorBoardTuesday #MedTwitter #MedX #cancer #Oncology

Very pleased to share this review on FGFR2b which is a key emerging biomarker in gastric and gastroesophageal #Cancer Looking forward to seeing those FORTITUDE 101 results soon 👀! Hopefully #ESMO25 in Berlin! Thanks 🙏 to all my co-authors! sciencedirect.com/science/articl…